Cargando…
A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients
This study aimed to evaluate and compare the efficacy and safety of mid-urethral sling (MUS) with botulinum toxin A (BoNT-A) versus MUS only in women with mixed urinary incontinence. This was a comparative observational study, and total of 73 patients were enrolled. A total of 38 and 35 patients rec...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354459/ https://www.ncbi.nlm.nih.gov/pubmed/32498306 http://dx.doi.org/10.3390/toxins12060365 |
_version_ | 1783558089296838656 |
---|---|
author | Chang, Yi-Huei Hsiao, Po-Jen Chi-Ping, Huang Wu, Hsi-Chin Hsieh, Po-Fan Chou, Eric Chieh-Lung |
author_facet | Chang, Yi-Huei Hsiao, Po-Jen Chi-Ping, Huang Wu, Hsi-Chin Hsieh, Po-Fan Chou, Eric Chieh-Lung |
author_sort | Chang, Yi-Huei |
collection | PubMed |
description | This study aimed to evaluate and compare the efficacy and safety of mid-urethral sling (MUS) with botulinum toxin A (BoNT-A) versus MUS only in women with mixed urinary incontinence. This was a comparative observational study, and total of 73 patients were enrolled. A total of 38 and 35 patients received MUS only and MUS with BoNT-A injection, respectively. The efficacy outcome included change in Urinary Incontinence Outcome Scores (UIOS), change in Overactive Bladder Symptom Score (OABSS), and use of antimuscarinic agent or beta-3 agonist. Safety assessments included adverse events including urinary retention, increased postvoid residual volumes, and urinary tract infection. MUS with BoNT-A injection was insignificantly better than MUS only in urinary incontinence outcome (88% vs. 71%, respectively, p = 0.085) at week three. Among the 33 patients with detrusor overactivity (DO), patients who received BoNT-A had a higher cure rate of incontinence (88% vs. 41%, p = 0.01) and less required antimuscarinic agent or beta-3 agonist (31% vs. 94%, p < 0.001) compared to patients who did not receive BoNT-A injection. There was no significant difference in the incidences of adverse events between two groups. BoNT-A injection with MUS demonstrated efficacy and safety in the treatment of mixed urinary incontinence, specifically for women with DO. |
format | Online Article Text |
id | pubmed-7354459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73544592020-08-05 A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients Chang, Yi-Huei Hsiao, Po-Jen Chi-Ping, Huang Wu, Hsi-Chin Hsieh, Po-Fan Chou, Eric Chieh-Lung Toxins (Basel) Article This study aimed to evaluate and compare the efficacy and safety of mid-urethral sling (MUS) with botulinum toxin A (BoNT-A) versus MUS only in women with mixed urinary incontinence. This was a comparative observational study, and total of 73 patients were enrolled. A total of 38 and 35 patients received MUS only and MUS with BoNT-A injection, respectively. The efficacy outcome included change in Urinary Incontinence Outcome Scores (UIOS), change in Overactive Bladder Symptom Score (OABSS), and use of antimuscarinic agent or beta-3 agonist. Safety assessments included adverse events including urinary retention, increased postvoid residual volumes, and urinary tract infection. MUS with BoNT-A injection was insignificantly better than MUS only in urinary incontinence outcome (88% vs. 71%, respectively, p = 0.085) at week three. Among the 33 patients with detrusor overactivity (DO), patients who received BoNT-A had a higher cure rate of incontinence (88% vs. 41%, p = 0.01) and less required antimuscarinic agent or beta-3 agonist (31% vs. 94%, p < 0.001) compared to patients who did not receive BoNT-A injection. There was no significant difference in the incidences of adverse events between two groups. BoNT-A injection with MUS demonstrated efficacy and safety in the treatment of mixed urinary incontinence, specifically for women with DO. MDPI 2020-06-02 /pmc/articles/PMC7354459/ /pubmed/32498306 http://dx.doi.org/10.3390/toxins12060365 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chang, Yi-Huei Hsiao, Po-Jen Chi-Ping, Huang Wu, Hsi-Chin Hsieh, Po-Fan Chou, Eric Chieh-Lung A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients |
title | A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients |
title_full | A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients |
title_fullStr | A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients |
title_full_unstemmed | A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients |
title_short | A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients |
title_sort | comparative observational study to evaluate the efficacy of mid-urethral sling with botulinum toxin a injection in urinary incontinence patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354459/ https://www.ncbi.nlm.nih.gov/pubmed/32498306 http://dx.doi.org/10.3390/toxins12060365 |
work_keys_str_mv | AT changyihuei acomparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT hsiaopojen acomparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT chipinghuang acomparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT wuhsichin acomparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT hsiehpofan acomparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT chouericchiehlung acomparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT changyihuei comparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT hsiaopojen comparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT chipinghuang comparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT wuhsichin comparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT hsiehpofan comparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients AT chouericchiehlung comparativeobservationalstudytoevaluatetheefficacyofmidurethralslingwithbotulinumtoxinainjectioninurinaryincontinencepatients |